1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Resverlogix Corp. - Product Pipeline Review - 2015

Resverlogix Corp. - Product Pipeline Review - 2015

  • September 2015
  • -
  • Global Markets Direct
  • -
  • 32 pages

Resverlogix Corp. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Resverlogix Corp. - Product Pipeline Review - 2015’, provides an overview of the Resverlogix Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Resverlogix Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Resverlogix Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Resverlogix Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Resverlogix Corp.’s pipeline products

Reasons to buy

- Evaluate Resverlogix Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Resverlogix Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Resverlogix Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Resverlogix Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Resverlogix Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Resverlogix Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Resverlogix Corp. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Resverlogix Corp. Snapshot 4
Resverlogix Corp. Overview 4
Key Information 4
Key Facts 4
Resverlogix Corp. - Research and Development Overview 5
Key Therapeutic Areas 5
Resverlogix Corp. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Resverlogix Corp. - Pipeline Products Glance 9
Resverlogix Corp. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Resverlogix Corp. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Resverlogix Corp. - Unknown Stage Pipeline Products 12
Unknown Products/Combination Treatment Modalities 12
Resverlogix Corp. - Drug Profiles 13
apabetalone 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
RVX-2135 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
RVX-297 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Small Molecules to Activate ApoA-I for Alzheimer's Disease 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Resverlogix Corp. - Pipeline Analysis 19
Resverlogix Corp. - Pipeline Products by Target 19
Resverlogix Corp. - Pipeline Products by Route of Administration 20
Resverlogix Corp. - Pipeline Products by Molecule Type 21
Resverlogix Corp. - Pipeline Products by Mechanism of Action 22
Resverlogix Corp. - Recent Pipeline Updates 23
Resverlogix Corp. - Dormant Projects 29
Resverlogix Corp. - Locations And Subsidiaries 30
Head Office 30
Other Locations and Subsidiaries 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 31
Disclaimer 32

List of Tables
Resverlogix Corp., Key Information 4
Resverlogix Corp., Key Facts 4
Resverlogix Corp. - Pipeline by Indication, 2015 6
Resverlogix Corp. - Pipeline by Stage of Development, 2015 7
Resverlogix Corp. - Monotherapy Products in Pipeline, 2015 8
Resverlogix Corp. - Phase II, 2015 9
Resverlogix Corp. - Preclinical, 2015 10
Resverlogix Corp. - Discovery, 2015 11
Resverlogix Corp. - Unknown, 2015 12
Resverlogix Corp. - Pipeline by Target, 2015 19
Resverlogix Corp. - Pipeline by Route of Administration, 2015 20
Resverlogix Corp. - Pipeline by Molecule Type, 2015 21
Resverlogix Corp. - Pipeline Products by Mechanism of Action, 2015 22
Resverlogix Corp. - Recent Pipeline Updates, 2015 23
Resverlogix Corp. - Dormant Developmental Projects,2015 29
Resverlogix Corp., Other Locations 30

List of Figures
Resverlogix Corp. - Pipeline by Top 10 Indication, 2015 6
Resverlogix Corp. - Pipeline by Stage of Development, 2015 7
Resverlogix Corp. - Monotherapy Products in Pipeline, 2015 8
Resverlogix Corp. - Pipeline by Top 10 Target, 2015 19
Resverlogix Corp. - Pipeline by Top 10 Route of Administration, 2015 20
Resverlogix Corp. - Pipeline by Top 10 Molecule Type, 2015 21
Resverlogix Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 ...

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2016

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2016 Summary Global Markets ...

Obesity - Pipeline Review, H2 2016

November 2016 $ 2500

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.